EUVIMEDEUVIMED entdecken
Crossref

Notoginsenoside R1 reduces acquired lymphedema and increases lymphangiogenesis by promoting VEGF-C expression via cAMP/PKA/CREB signaling

Jia-Min Bao, Tong Hou, Li Zhao, Yong-Jia Song, Yang Liu, Lian-Ping Xing, Hao Xu, Xiao-Yun Wang, Qing Li, Li Zhang, Jun-Li Chang, Wei Li und 3 weitere

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2025.156554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Jia-Min Bao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China; Spine Institute, Shanghai Univ…. Hauptthemen laut MEDLINE: Lymphangiogenesis, Vascular Endothelial Growth Factor C, Ginsenosides, Lymphedema. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acquired lymphedema is a global health concern with limited treatment options. While vascular endothelial growth factor C (VEGF-C) administration has shown promise for the treatment of this patient population, no small-molecule compounds have hitherto been identified to improve lymphedema by stimulating VEGF-C expression and lymphangiogenesis. OBJECTIVE: This study investigated the therapeutic effect of notoginsenoside R1 (R1) on a mouse model of tail acquired lymphedema and explored the underlying mechanisms. METHODS: C57BL/6J mice and lymphatic endothelial cells (LECs) specific VEGFR-3 knockout transgenic mice underwent surgical induction of tail acquired lymphedema. Tail circumference, lymphatic drainage function, VEGF-C expression, and lymphangiogenesis were measured. LECs' function was assessed using wound healing and tube formation assays. Quantitative PCR (q-PCR) and western blot were conducted to measure VEGF-C expression levels. In addition, RNA sequencing analysis and western blot were performed to elucidate the signal pathways involved. Luciferase reporter assays assessed VEGF-C promoter activity. RESULTS: R1 treatment improved lymphedema, lymphatic function, and lymphangiogenesis in the mouse model. R1 enhanced migration, tube formation, and VEGF-C expression of LECs. These effects were abolished by VEGF-C siRNA and VEGFR-3 inhibitors. VEGFR3 knockout in LECs completely blocked R1's ability to promote lymphangiogenesis and lymphatic drainage while partially but significantly reducing its improvement on lymphedema. R1 activated the cAMP/PKA signaling pathway, leading to PKA and CREB phosphorylation. The PKA inhibitor and CREB siRNA inhibited R1-induced VEGF-C expression. Additionally, R1 activated VEGF-C promoter activity in a CREB-dependent manner. CONCLUSION: R1 emerges as the first reported small natural compound to promote VEGF-C expression. It reduces acquired lymphedema and enhances lymphangiogenesis via the cAMP/PKA/CREB signaling pathway. These findings suggest R1 as a potential novel oral medication for treating acquired lymphedema patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangiogenesisVascular Endothelial Growth Factor CGinsenosidesLymphedemaAnimalsSignal TransductionMice, Inbred C57BLCyclic AMP Response Element-Binding ProteinCyclic AMP-Dependent Protein KinasesMiceCyclic AMPVascular Endothelial Growth Factor Receptor-3Mice, KnockoutEndothelial CellsDisease Models, AnimalMale

Stichwörter der Autor:innen

LymphangiogenesisLymphedemaNotoginsenoside R1VEGF-CcAMP/PKA/CREB

Substanzen

Vascular Endothelial Growth Factor CCyclic AMP Response Element-Binding ProteinGinsenosidesCyclic AMP-Dependent Protein KinasesCyclic AMPVascular Endothelial Growth Factor Receptor-3notoginsenoside R1Creb1 protein, mousevascular endothelial growth factor C, mouse

Autor:innen und Institutionen

  • Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China; Spine Institute, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shangh…
  • Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China; Jing'an District Central Hospital, Shanghai 200040, China.
  • Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, United States.
  • Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China; Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Bao, J. M., Hou, T., Zhao, L., Song, Y. J., Liu, Y., Xing, L. P., Xu, H., Wang, X. Y., Li, Q., Zhang, L., Chang, J. L., Li, W., Shi, Q., Wang, Y. J., & Liang, Q. Q. (2025). Notoginsenoside R1 reduces acquired lymphedema and increases lymphangiogenesis by promoting VEGF-C expression via cAMP/PKA/CREB signaling. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.156554

Vancouver

Bao JM, Hou T, Zhao L, Song YJ, Liu Y, Xing LP, et al. Notoginsenoside R1 reduces acquired lymphedema and increases lymphangiogenesis by promoting VEGF-C expression via cAMP/PKA/CREB signaling. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.156554

BibTeX
@article{Bao2025,
  author = {Bao, Jia-Min and Hou, Tong and Zhao, Li and Song, Yong-Jia and Liu, Yang and Xing, Lian-Ping and Xu, Hao and Wang, Xiao-Yun and Li, Qing and Zhang, Li and Chang, Jun-Li and Li, Wei and Shi, Qi and Wang, Yong-Jun and Liang, Qian-Qian},
  title = {Notoginsenoside R1 reduces acquired lymphedema and increases lymphangiogenesis by promoting VEGF-C expression via cAMP/PKA/CREB signaling},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2025.156554}
}
Kostenlos starten →